Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models

European Journal of Pharmacology

Volumn 550, Issue 1-3, 2006, Pages 166-172

  Yamamoto, Satoshi ^a   Sugahara, Shingo ^a   Ikeda, Ken ^a   Shimizu, Yasuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cyclosporine; Immunosuppressant; Neutrophil; Phosphodiesterase 4; Phosphodiesterase 7A; Th cell; YM 393059

Indexed keywords

CARRAGEENAN; CYCLOSPORIN; DICLOFENAC; FUMARIC ACID DERIVATIVE; IMMUNOGLOBULIN E; N (4,6 DIMETHYLPYRIMIDIN 2 YL) 4 [2 (4 METHOXY 3 METHYLPHENYL) 5 (4 METHYLPIPERAZIN 1 YL) 4,5,6,7 TETRAHYDRO 1H INDOL 1 YL]BENZENESULFONAMIDE DIFUMARATE; PHOSPHODIESTERASE INHIBITOR; TOLUENE DIISOCYANATE; UNCLASSIFIED DRUG; YM 393059; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG EFFECT; ERYTHROCYTE; INFLAMMATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SHEEP; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CHRONIC DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; CYCLOSPORINE; DERMATITIS, CONTACT; EDEMA; ERYTHROCYTES; FUMARATES; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; INDOLES; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; PERITONITIS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SHEEP; SULFONAMIDES; TOLUENE 2,4-DIISOCYANATE; ZYMOSAN;

EID: 33749986292     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.023     Document Type: Article

References (43)

1. Anderson R., Mahomed A.G., Theron A.J., Ramafi G., and Feldman C. Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. Br. J. Pharmacol. 124 (1998) 547-555
2. Aramburu J., Rao A., and Klee C.B. Calcineurin: from structure to function. Curr. Top. Cell. Regul. 36 (2000) 237-295
3. Borel J.F., Feurer C., Gubler H.U., and Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6 (1976) 468-475
4. Borel J.F., Feurer C., Magnee C., and Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32 (1977) 1017-1025
5. Cher D.J., and Mosmann T.R. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 138 (1987) 3688-3694
6. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63 (1999) 1-38
7. Cooper K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J. Invest. Dermatol. 102 (1994) 128-137
8. Del Prete G., Maggi E., Parronchi P., Chretien I., Tiri A., Macchia D., Ricci M., Banchereau J., De Vries J., and Romagnani S. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J. Immunol. 140 (1988) 4193-4198
9. Doherty N.S., Poubelle P., Borgeat P., Beaver T.H., Westrich G.L., and Schrader N.L. Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. Prostaglandins 30 (1985) 769-789
10. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65 (2001) 1-52
11. Gardner C., Robas N., Cawkill D., and Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 272 (2000) 186-192
12. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 59 (2000) 193-212
13. Giembycz M.A. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 57 (2002) 48-64
14. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., and Barnes P.J. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118 (1996) 1945-1958
15. Green C.J. Immunosuppression with cyclosporin A: a review. Diagn. Histopathol. 4 (1981) 157-174
16. Hanifin J.M. Atopic dermatitis: new therapeutic considerations. J. Am. Acad. Dermatol. 24 (1991) 1097-1101
17. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson Jr. W.R., Kirby D.S., and Weiner E.S. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107 (1996) 51-56
18. Hetman J.M., Soderling S.H., Glavas N.A., and Beavo J.A. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 472-476
19. Huang Z., Ducharme Y., Macdonald D., and Robichaud A. The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. 5 (2001) 432-438
20. Janossy G., Panayi G., Duke O., Bofill M., Poulter L.W., and Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2 (1981) 839-842
21. Li L., Yee C., and Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283 (1999) 848-851
22. Lin C.S., Lau A., Tu R., and Lue T.F. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem. Biophys. Res. Commun. 268 (2000) 628-635
23. Liu J., Farmer Jr. J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
24. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136 (1986) 2348-2357
25. Nagai H., Hiyama H., Matsuo A., Ueda Y., Inagaki N., and Kawada K. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. J. Pharmacol. Exp. Ther. 283 (1997) 321-327
26. Numano F., Kishi Y., and Ashikaga T. Clinical studies of phosphodiesterase inhibitors for cardiovascular disease. Adv. Second Messenger Phosphoprot. Res. 25 (1992) 395-407
27. Parronchi P., Tiri A., Macchia D., De Carli M., Biswas P., Simonelli C., Maggi E., Del Prete G., Ricci M., and Romagnani S. Noncognate contact-dependent B cell activation can promote IL-4-dependent in vitro human IgE synthesis. J. Immunol. 144 (1990) 2102-2108
28. Perry M.J., and Higgs G.A. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr. Opin. Chem. Biol. 2 (1998) 472-481
29. Polson J.B., and Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 403-427
30. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol. Today 12 (1991) 256-257
31. Romero A., Planas E., Poveda R., Sanchez S., Pol O., and Puig M.M. Anti-exudative effects of opioid receptor agonists in a rat model of carrageenan-induced acute inflammation of the paw. Eur. J. Pharmacol. 511 (2005) 207-217
32. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 1 (2002) 674-682
33. Sasaki T., Kotera J., Yuasa K., and Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 271 (2000) 575-583
34. Scheerens H., Buckley T.L., Davidse E.M., Garssen J., Nijkamp F.P., and Van Loveren H. Toluene diisocyanate-induced in vitro tracheal hyperreactivity in the mouse. Am. J. Respir. Crit. Care Med. 154 (1996) 858-865
35. Scheerens H., Buckley T.L., Muis T.L., Garssen J., Dormans J., Nijkamp F.P., and Van Loveren H. Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge. Am. J. Respir. Crit. Care Med. 159 (1999) 1074-1080
36. Souness J.E., Aldous D., and Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47 (2000) 127-162
37. Tarayre J.P., Delhon A., Aliaga M., Barbara M., Bruniquel F., Caillol V., Puech L., Consul N., and Tisne-Versailles J. Pharmacological studies on zymosan inflammation in rats and mice. 1: Zymosan-induced paw oedema in rats and mice. Pharmacol. Res. 21 (1989) 375-384
38. Tarayre J.P., Barbara M., Aliaga M., and Tisne-Versailles J. Comparative actions of immunosuppressants, glucocorticoids and non-steroidal anti-inflammatory drugs on various models of delayed hypersensitivity and on a non-immune inflammation in mice. Arzneim.-Forsch. 40 (1990) 1125-1131
39. Teixeira M.M., Gristwood R.W., Cooper N., and Hellewell P.G. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future?. Trends Pharmacol. Sci. 18 (1997) 164-171
40. Thomson A.W., Whiting P.H., and Simpson J.G. Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions 15 (1984) 306-327
41. White D.J., Plumb A.M., Pawelec G., and Brons G. Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells. Transplantation 27 (1979) 55-58
42. Winter C.A., Risley E.A., and Nuss G.W. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111 (1962) 544-547
43. Yamamoto S., Sugahara S., Naito R., Ichikawa A., Ikeda K., Yamada T., and Shimizu Y. The effects of a novel phosphodiesterase 7A and-4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur. J. Pharmacol. 541 (2006) 106-114